Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of MEDI7352 in painful diabetic neuropathy
2018-002523-42Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MEDI7352 in diabetic neuropathy (4 arms), sponsored by AstraZeneca. Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
MEDI7352
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on 2018-002523-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002523-42.